Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Succinimide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.73 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGAV | P06756 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinimide SCHEMBL6717091 | 1.00 | CRBN (0.73) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL6036901 | 1.00 | CRBN (0.73) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL938030 | 0.94 | CRBN (0.65) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL9729105 | 0.90 | CRBN (0.69) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL30109359 | 0.90 | CRBN (0.69) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL6153012 | 0.89 | CRBN (0.58) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL20786978 | 0.89 | CRBN (0.58) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL11381109 | 0.88 | CRBN (0.65) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL20299953 | 0.88 | CRBN (0.65) | CRBNITGB3ITGB1ITGAVITGA4 | |
| Succinimide SCHEMBL30804677 | 0.88 | CRBN (0.65) | CRBNITGB3ITGB1ITGAVITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188142-A1 | POLYETHYLENE GLYCOL DERIVATIVE MODIFIED INTERLEUKIN-12, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KANGLITAI BIOMEDICAL (QINGDAO) CO., LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| CN-119499457-A | Coating composition for preventing medical instrument from crusting, and preparation method and application thereof | 中国科学院理化技术研究所 | 2025-02-25 | — | — | CN | claimed |
| CN-116077744-B | Absorbable self-developing hydrogel and preparation method and application thereof | 清华大学 | 2024-11-12 | — | — | CN | claimed |
| CN-114989289-B | Novel insulin analogues and uses thereof | 韩美药品株式会社 | 2024-10-01 | — | — | CN | claimed |
| EP-4410826-A1 | POLYETHYLENE GLYCOL DERIVATIVE MODIFIED INTERLEUKIN-12, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Kanglitai Biomedical (Qingdao) Co., Ltd. (CN) | 2024-08-07 | — | — | EP | claimed |
| US-11844842-B2 | Composition of polyethylene glycol maleimide derivative and polymerization inhibitor | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2023-12-19 | — | — | US | claimed |
| CN-117106439-A | Fluorescent emitter for HeLa cell imaging, preparation method and imaging system | 上海理工大学 | 2023-11-24 | — | — | CN | claimed |
| CN-116077744-A | Absorbable self-developing hydrogel and preparation method and application thereof | 清华大学 | 2023-05-09 | — | — | CN | claimed |
| CN-115970065-A | Medical instrument bag for isolating and sealing osteogenic area and application of medical instrument bag in dental implant surgery | 江苏博创生物科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-115919755-A | Low-concentration hydrogel and preparation method and application thereof | 沈阳药科大学 | 2023-04-07 | — | — | CN | claimed |
| CN-103462933-B | The polyethyleneglycol modified lipid nanometer delivery system of death ligand antibody coupling and application | ZHEJIANG UNIVERSITY (CN) | 2015-10-21 | — | — | CN | claimed |
| CN-101537345-B | Preparation method of modified cyclodextrin chiral hybrid monolithic chromatogram stationary phase | SOOCHOW HIGH TECH CHROMATOGRAPHY CO LTD | 2010-12-29 | — | — | CN | claimed |
| US-20090281330-A1 | Nitrons Carrying a Positive Charge and Usable in Trapping Free Radicals, Especially the Superoxide Radical | TORDO PAUL | 2009-11-12 | — | — | US | claimed |
| CN-101537345-A | Preparation method of modified cyclodextrin chiral hybrid monolithic chromatogram stationary phase | SOOCHOW HIGH TECHNOLOGY CHROMA | 2009-09-23 | — | — | CN | claimed |
| US-20080009636-A1 | Nitrons carrying a positive charge and usable in trapping free radicals, especially the superoxide radical | UNIVERSITE D'AIX-MARSEILLE (FR) | 2008-01-10 | — | — | US | claimed |
| EP-0893439-B1 | A process for forming a modified polypeptide comprising a polypeptide and a polyalkylene oxide | ENZON INC (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1352072-A4 | NUCLEIC ACID DELIVERY FORMULATIONS | ZYCOS INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040147466-A1 | Nucleic acid delivery formulations | MGI PHARMA BIOLOGICS, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1352072-A2 | NUCLEIC ACID DELIVERY FORMULATIONS | Zycos Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002057424-A2 | NUCLEIC ACID DELIVERY FORMULATIONS | ZYCOS INC. (US) | 2002-07-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281330-A1 | Nitrons Carrying a Positive Charge and Usable in Trapping Free Radicals, Especially the Superoxide Radical | SOD1, TXN2, NOX1 | CRBN 818/4885ITGB3 1444/4885ITGB1 1028/4885 |
| US-20080009636-A1 | Nitrons carrying a positive charge and usable in trapping free radicals, especially the superoxide radical | SOD1, TXN2, NOX1 | CRBN 818/4885ITGB3 1444/4885ITGB1 1028/4885 |
| US-11844842-B2 | Composition of polyethylene glycol maleimide derivative and polymerization inhibitor | TFPI, PCNA, CCNI | CRBN 430/4885ITGB3 3619/4885ITGB1 3381/4885 |
| US-20250188142-A1 | POLYETHYLENE GLYCOL DERIVATIVE MODIFIED INTERLEUKIN-12, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CASP12, IL2, SUZ12 | CRBN 344/4885ITGB3 2978/4885ITGB1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.